Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML3453

Sigma-Aldrich

MGCD0103

≥95% (HPLC)

Synonym(s):

MGCD, MGCD 0103, MGCD-0103, Mocetinostat, N-(2-Amino-phenyl)-4-((4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl)-benzamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C23H20N6O
CAS Number:
726169-73-9
Molecular Weight:
396.44
MDL number:
MFCD10565970
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

InChI

1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)

InChI key

HRNLUBSXIHFDHP-UHFFFAOYSA-N

Biochem/physiol Actions

MGCD0103 (Mocetinostat) is an orally active, potent and subtype-selective histone deacetylase (HDAC) inhibitor (IC50: class I HDAC1/2/3 = 0.15/0.29/1.66 μM, class IV HDAC11 = 0.59 μM, HDAC4/5/7/8 >10 μM) that effectively inhibits cellular HDAC activity (IC50 = 450 nM; Du145, HCT15, HCT116), resulting in an upregulated acetylation of histone H3 and H4, but not that of tubulin. MGCD0103 daily orally administration (60-120 mg/kg) is efficacious against A549 & H1437 tumor growth in mice in vivo.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Marielle Fournel et al.
Molecular cancer therapeutics, 7(4), 759-768 (2008-04-17)
Nonselective inhibitors of human histone deacetylases (HDAC) are known to have antitumor activity in mice in vivo, and several of them are under clinical investigation. The first of these, Vorinostat (SAHA), has been approved for treatment of cutaneous T-cell lymphoma.
Hanna Jung et al.
BioMed research international, 2020, 4705615-4705615 (2020-08-11)
The use of histone deacetylase (HDAC) inhibitor is a novel therapeutic strategy for cardiovascular disease. Studies have shown that many HDAC inhibitors have the ability to reduce the aortic remodeling in various animal models. We hypothesized that the HDAC inhibitor
W-J Wu et al.
European review for medical and pharmacological sciences, 24(8), 4467-4475 (2020-05-07)
To investigate the effect and mechanism of mocetinostat on diminishing epidural fibrosis. Dysregulated wound repair usually occurs after injury or surgery and is featured by excessive scar tissue contributed by fibrosis. Increasing researches demonstrated that histone acetylation, an epigenetic alteration
W-J Wu et al.
European review for medical and pharmacological sciences, 25(9), 3396-3396 (2021-05-19)
The article "Mocetinostat suppresses epidural fibrosis following laminectomy by inhibiting myofibroblast activation and increasing apoptosis, by W.-J. Wu, J. Wang, J. Liang, Q. Zhou, Y. Liang, published in Eur Rev Med Pharmacol Sci 2020; 24 (8): 4467-4475-DOI: 10.26355/eurrev_202004_21029-PMID: 32373984" has
Bo Liao et al.
Journal of Cancer, 11(7), 1915-1926 (2020-03-21)
Background: Liver cancer is a common cause of cancer-related death all over the world. MGCD0103, a histone deacetylase inhibitor, exerts antitumor effect on various cancers. However, its role in liver cancer remains unclear. Methods: The effect of MGCD0103 on HepG2

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service